Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...
News-Medical.Net on MSN14h
New insights into therapy resistance in breast cancer
A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...